Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab versus docetaxel in previously treated non-small cell lung cancer
2012-004391-19Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2013
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Merck & Co. Primary endpoints: Overall survival and Progression-free survival. Started Jan 2013; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2012-004391-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004391-19.